These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 29111299)

  • 1. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia.
    Ohno-Matsui K; Ikuno Y; Lai TYY; Gemmy Cheung CM
    Prog Retin Eye Res; 2018 Mar; 63():92-106. PubMed ID: 29111299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-VEGF Therapy in Myopic CNV.
    Toto L; Di Antonio L; Costantino O; Mastropasqua R
    Curr Drug Targets; 2021; 22(9):1054-1063. PubMed ID: 33511955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
    Pakzad-Vaezi K; Mehta H; Mammo Z; Tufail A
    Expert Opin Biol Ther; 2016 Jul; 16(7):873-81. PubMed ID: 26985834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management.
    Cheung CMG; Arnold JJ; Holz FG; Park KH; Lai TYY; Larsen M; Mitchell P; Ohno-Matsui K; Chen SJ; Wolf S; Wong TY
    Ophthalmology; 2017 Nov; 124(11):1690-1711. PubMed ID: 28655539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and Diagnosis of Myopic Choroidal Neovascularization in Asia.
    Chan NS; Teo K; Cheung CM
    Eye Contact Lens; 2016 Jan; 42(1):48-55. PubMed ID: 26448447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization.
    Ng DSC; Lai TYY; Cheung CMG; Ohno-Matsui K
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):554-560. PubMed ID: 29057641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab for myopic choroidal neovascularization.
    Ng DSC; Fung NSK; Yip FLT; Lai TYY
    Expert Opin Biol Ther; 2020 Dec; 20(12):1385-1393. PubMed ID: 33003962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook.
    Munk MR; Rückert R; Zinkernagel M; Ebneter A; Wolf S
    Expert Opin Biol Ther; 2016; 16(4):477-87. PubMed ID: 26666589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
    Ahn SJ; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
    Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia.
    Battaglia Parodi M; Iacono P; Bandello F
    Dev Ophthalmol; 2010; 46():73-83. PubMed ID: 20703033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
    Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS; Kim JG; Kim JT; Joe SG
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Visual Outcome and Low Recurrence with Early Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor in Myopic Choroidal Neovascularization.
    Moon BG; Cho AR; Lee J; Kim YJ; Lee JY; Kim JG; Yoon YH
    Ophthalmologica; 2017; 237(3):128-138. PubMed ID: 28278507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application.
    Zhang Y; Han Q; Ru Y; Bo Q; Wei RH
    Drug Des Devel Ther; 2015; 9():3413-21. PubMed ID: 26170626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor for myopic choroidal neovascularization.
    Ng DS; Kwok AK; Chan CW
    Clin Exp Ophthalmol; 2012; 40(1):e98-e110. PubMed ID: 21902785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
    Yoon JU; Byun YJ; Koh HJ
    Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myopic choroidal neovascularisation: current concepts and update on clinical management.
    Wong TY; Ohno-Matsui K; Leveziel N; Holz FG; Lai TY; Yu HG; Lanzetta P; Chen Y; Tufail A
    Br J Ophthalmol; 2015 Mar; 99(3):289-96. PubMed ID: 24990871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
    Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
    Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T;
    Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.